Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1459 • ACR Convergence 2024
Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity
Michael Nissen¹, Adrian Ciurea², Raphael Micheroli³, Eric Trunk⁴ and Delphine Courvoisier⁵, ¹Geneva University Hospital, Geneva, Switzerland, ²University Hospital Zurich, Zürich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴Geneva University Hospital, Geenva, Switzerland, ⁵University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: Current EULAR recommendations highlight the importance of a healthy, balanced diet in patients with inflammatory rheumatic disease, including axial spondylarthritis (axSpA). A Mediterranean-style diet…
Abstract Number: 2119 • ACR Convergence 2024
IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures
Chloe Heiting¹, Donald McMahon¹, Douglas Mintz¹, Weijia Yuan¹, Insa Mannstadt¹, Linda A Russell¹, Emily Stein¹, Dalit Ashany² and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Scarsdale, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Axial spondyloarthritis (AxSpA) is characterized by abnormal bone formation and, paradoxically, bone loss accompanied by increased bone fragility and vertebral fracture risk. Tumor necrosis…
Abstract Number: 0081 • ACR Convergence 2024
The Axial Spondyloarthritis Risk Variant CARD9 S12N Enhances Neutrophil-mediated Th Responses
Hillary Struthers¹, Kofi Asare-Konadu², Emily Vance¹ and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the entheses of the spine and/or sacroiliac joints. The cause of axSpA…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 1054 • ACR Convergence 2024
Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review
Keri Geinosky¹, Joel Thompson², Joshua Torrey³ and Louise Thoma⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, ²university of north carolina - chapel hill, Cary, NC, ³UNC Chapel Hill, Westmoreland, NH, ⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: Rehabilitation services, such as physical therapy (PT) and occupational therapy (OT), are recommended in the care of inflammatory arthritis and other rheumatic conditions. However, the…
Abstract Number: 1475 • ACR Convergence 2024
Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
Raj Sengupta¹, Pedro M Machado², Philippe Goupille³, Victoria Navarro Compán⁴, Huji Xu⁵, mohamed sheesh⁶, Khai Jing Ng⁷, Marcus Ngantcha⁸, Hagen Russ⁹, Gabriel Doridot⁶ and Xenofon Baraliakos¹⁰, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ³UPR CNRS 4301 CBM, NMNS, University of Tours; Department of Rheumatology, University hospital, Tours, Tours, France, ⁴La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁵Changzheng Hospital, Naval Medical University, Shanghai, China, Shanghai, China (People's Republic), ⁶Eli Lilly, Indianopolis, IN, ⁷Eli Lilly and Company, Madrid, Spain, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Indianopolis, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Elevated baseline (BL) C-reactive protein (CRP) level can serve as a predictor for treatment response to TNF inhibitors in patients (pts) with r-axSpA. The…
Abstract Number: 2138 • ACR Convergence 2024
DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher², Zhivana Boydzhieva³, andriko Palmowski⁴, Sandra Hermann⁵, burkhard Muche⁵, Gerhard Krönke⁵ and FRANK HARTMUT DR. BUTTGEREIT¹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Charité Universittsmedizin, Berlin, Germany, ⁴Charité - Universittsmedizin Berlin, Berlin, Germany, ⁵Rheumatology, Charité, Berlin, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis and fragility fracture risk that may not be reflected by areal bone mineral density (aBMD) measurements alone.…
Abstract Number: 0083 • ACR Convergence 2024
Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice
Mariia Korshko¹, Shaghayegh Foroozan Boroojeni² and Nigil Haroon³, ¹University Health Network, Toronto, ON, Canada, ²UHN, Toronto, Canada, ³Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
Abstract Number: 0570 • ACR Convergence 2024
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Halah Alfatlawi¹, abdulmajeed alharbi², eun seo kwak², rawnag el sheikh² and nezam altorok², ¹the university of toledo, Toledo, OH, ²the university of toledo, Toledo
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1476 • ACR Convergence 2024
Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Joyce Samuel⁴, Charles Green², Jon Tyson⁴ and John Reveille⁵, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UTHealth Houston, Houston, TX, ⁵UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line pharmacological treatment for Axial Spondyloarthritis (axSpA), yet individual responses to different NSAIDs vary significantly. This study aims…
Abstract Number: 2156 • ACR Convergence 2024
Differential Item Functioning of Inflammatory Back Pain Criteria in US Subpopulations
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Alexis Ogdie⁴, Michael Weisman⁵, John Reveille⁶ and Charles Green², ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Stanford University, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: IInflammatory back pain (IBP) has clinical features that distinguish it from other back pain etiologies. While there are established IBP criteria, in different subpopulations…
Abstract Number: 0224 • ACR Convergence 2024
How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries
Anna EF Hadsbjerg¹, Simon Krabbe², Nora Vladimirova², Adrian Ciurea³, Kristyna Bubova⁴, Monika Gregová⁴, Michael Nissen⁵, Burkhard Moeller⁶, Raphael Micheroli⁷, Susanne Pedersen⁸, Jakub Zavada⁴, Ziga Snoj⁹, Karlo Pintaric⁹, Bjorn Gudbjornsson¹⁰, Ziga Rotar¹¹, iris Eshed¹², Iwona Sudol-Szopinska¹³, Kasper Gosvig¹⁴, Torsten Diekhoff¹⁵, Robert Lambert¹⁶, Manouk de hOoge¹⁷, Helena V G Elmo¹, Merete Hetland¹⁸, Lykke Oernbjerg¹⁹ and Mikkel Ostergaard²⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, ³University Hospital Zurich, Zürich, Switzerland, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁵Geneva University Hospital, Geneva, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷University Hospital Zurich, Zurich, Switzerland, ⁸Rigshospitalet, København, Denmark, ⁹Institute of Radiology, UMC Ljubljana, Ljubljana, Slovenia, ¹⁰Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Sheba Medical Center, Tel Hashomer affiliated with School of medicine, Tel Aviv University, Department of Diagnostic Imaging, Tel Aviv, Israel, ¹³Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, ¹⁴Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, ¹⁵Charite Universitatsmedizin Berlin, Berlin, Germany, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ¹⁸Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹⁹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: MRI of the sacroiliac joints (SIJs) is widely used for diagnosing and monitoring patients with spondyloarthritis (SpA). However, local radiologists might be less familiar with…
Abstract Number: 0573 • ACR Convergence 2024
Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
Ansaam Daoud¹, Jennifer Murphy², Omer Pamuk³ and Marina Magrey⁴, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: A large proportion of patients with ankylosing spondylitis (AS) are considered difficult to treat (D2T).The study aimed to compare baseline characteristics, extra-articular manifestations (EAM),…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…

« Previous Page
1
…
3
4
5
6
7
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.